Palatin Technologies (PTN) Non-Current Assets (2011 - 2026)
Palatin Technologies' (PTN) quarterly Non-Current Assets came in at $440089.0 in Q1 2026, down 11.13% on a YoY basis from $495216.0 in Q1 2025, and down 4.38% quarter-over-quarter from $460249.0 in Q4 2025.
Analysis
Palatin Technologies (PTN) Non-Current Assets (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Non-Current Assets for 15 consecutive years, with $440089.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 11.13% year-over-year to $440089.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 48.72% YoY), and the FY2025 full-year result was $347526.0, down 64.27% from the prior year.
- Non-Current Assets slipped to $440089.0 in Q1 2026 per PTN's latest filing, from $460249.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.6 million in Q2 2023 and bottomed at $244882.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $1.0 million across 5 years, with a median of $1.1 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets gained 9.71% in 2023, then slumped 69.49% in 2025.
- Over 5 years, Non-Current Assets stood at $1.4 million in 2022, then slipped by 8.13% to $1.3 million in 2023, then sank by 51.1% to $640301.0 in 2024, then declined by 28.12% to $460249.0 in 2025, then dropped by 4.38% to $440089.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $440089.0, $460249.0, and $244882.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 440,089.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 440,089.00 |
| Dec 31, 2025 | 460,249.00 |
| Sep 30, 2025 | 244,882.00 |
| Jun 30, 2025 | 347,526.00 |
| Mar 31, 2025 | 495,216.00 |
| Dec 31, 2024 | 640,301.00 |
| Sep 30, 2024 | 802,610.00 |
| Jun 30, 2024 | 972,598.00 |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 1.63 Mn |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 1.39 Mn |